There are no fasting rules, no fluid restrictions, and no daily timing windows to manage
Avoid: All GLP-1 patches until Phase 3 clinical trials demonstrate their efficacy, which is not expected until 2030 or later, when microneedle technology may enable effective transdermal delivery of medications like semaglutide
Injectable GLP-1s may be more suitable for: Patients aiming for the maximum possible reduction in body weight, those with co-existing conditions like heart disease or chronic kidney disease (due to specific FDA approvals for Ozempic), or those who prefer a simple weekly medication schedule
These receptors slow down the rate of gastric emptying by relaxing stomach muscles
They also help the body produce less glucose (sugar) from the food you eat and improves your bodys response to insulin
Guidance for industry diabetes mellitus evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes